Are you Dr. Schranz?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
51 Goldfinch Cir
Phoenixville, PA 19460Phone+1 610-585-6294
Summary
- Dr. Jennifer Schranz, MD is an infectious disease specialist in Phoenixville, Pennsylvania. She is currently licensed to practice medicine in Pennsylvania.
Education & Training
University of Toronto Faculty of MedicineClass of 1989
Certifications & Licensure
PA State Medical License 1998 - 2026
Publications & Presentations
PubMed
- 25 citationsA Multicenter Evaluation of the US Prevalence and Regional Variation in Macrolide-Resistant S. pneumoniae in Ambulatory and Hospitalized Adult Patients in the United S...Vikas Gupta, Kalvin Yu, Jennifer Schranz, Steven P Gelone
Open Forum Infectious Diseases. 2021-02-04 - 3 citationsReply to Tang and LaiThomas M. File, Steven P Gelone, Jennifer Schranz, Elizabeth Alexander
Clinical Infectious Diseases. 2020-09-12 - 3 citationsHealth-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or M...Thomas P. Lodise, Sam Colman, Elizabeth Alexander, Daniel S Stein, David Fitts
Open Forum Infectious Diseases. 2020-06-01
Press Mentions
Nabriva to Present Data at the CHEST Annual Meeting Demonstrating the Safety and Efficacy of Newly FDA-Approved XENLETA (Lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)October 15th, 2019
Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical AssociationSeptember 27th, 2019- Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults with Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical TrialSeptember 27th, 2019
- Join now to see all
